Nuveen LLC Invests $29.44 Million in TG Therapeutics, Inc. $TGTX

Nuveen LLC acquired a new stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 746,696 shares of the biopharmaceutical company's stock, valued at approximately $29,442,000. Nuveen LLC owned 0.47% of TG Therapeutics as of its most recent SEC filing.

Several other large investors have also made changes to their positions in TGTX. CWM LLC lifted its holdings in shares of TG Therapeutics by 16.2% during the 1st quarter. CWM LLC now owns 2,085 shares of the biopharmaceutical company's stock valued at $82,000 after acquiring an additional 290 shares in the last quarter. Golden State Wealth Management LLC lifted its stake in shares of TG Therapeutics by 100.0% during the first quarter. Golden State Wealth Management LLC now owns 866 shares of the biopharmaceutical company's stock worth $34,000 after purchasing an additional 433 shares in the last quarter. Summit Investment Advisors Inc. boosted its position in shares of TG Therapeutics by 3.3% in the fourth quarter. Summit Investment Advisors Inc. now owns 14,606 shares of the biopharmaceutical company's stock worth $440,000 after buying an additional 463 shares during the period. Xponance Inc. raised its holdings in shares of TG Therapeutics by 5.3% during the 1st quarter. Xponance Inc. now owns 10,861 shares of the biopharmaceutical company's stock valued at $428,000 after buying an additional 543 shares during the period. Finally, Choreo LLC raised its holdings in shares of TG Therapeutics by 7.6% during the 1st quarter. Choreo LLC now owns 8,547 shares of the biopharmaceutical company's stock valued at $337,000 after buying an additional 602 shares during the period. 58.58% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, The Goldman Sachs Group upgraded TG Therapeutics to a "hold" rating and set a $37.00 price target on the stock in a research note on Thursday, July 10th. Three investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $46.25.

TG Therapeutics Stock Performance

TG Therapeutics stock traded up $0.39 during mid-day trading on Wednesday, reaching $28.31. The company's stock had a trading volume of 1,476,224 shares, compared to its average volume of 2,499,452. The company has a current ratio of 3.86, a quick ratio of 2.96 and a debt-to-equity ratio of 0.89. TG Therapeutics, Inc. has a twelve month low of $21.11 and a twelve month high of $46.48. The business has a 50 day moving average price of $34.60 and a 200-day moving average price of $35.78. The firm has a market cap of $4.49 billion, a price-to-earnings ratio of 76.51 and a beta of 1.95.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last posted its quarterly earnings results on Monday, August 4th. The biopharmaceutical company reported $0.17 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.32 by ($0.15). TG Therapeutics had a return on equity of 26.05% and a net margin of 13.31%.The business had revenue of $141.15 million during the quarter, compared to the consensus estimate of $147.76 million. During the same quarter in the previous year, the business posted $0.04 earnings per share. The company's quarterly revenue was up 92.1% compared to the same quarter last year. TG Therapeutics has set its FY 2025 guidance at EPS. Sell-side analysts predict that TG Therapeutics, Inc. will post 0.08 EPS for the current fiscal year.

Insider Activity at TG Therapeutics

In other news, Director Yann Echelard sold 10,000 shares of the stock in a transaction that occurred on Friday, June 13th. The stock was sold at an average price of $36.94, for a total transaction of $369,400.00. Following the sale, the director directly owned 228,816 shares in the company, valued at approximately $8,452,463.04. This represents a 4.19% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 10.64% of the company's stock.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.